Stocks TelegraphStocks Telegraph
Stock Ideas

IMGN Financial Statements and Analysis

NASDAQ : IMGN

ImmunoGen, Inc.

$31.24
0.005+0.02%
At Close 4:00 PM
Not Actively Trading
65.48
BESG ScoreESG Rating

IMGN FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

IMGN Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2023-09-302023-09-302023-06-302023-03-312022-12-31
reported currencyUSDUSDUSDUSDUSD
calendar year20242023202320232022
periodQ1Q3Q2Q1Q4
revenue113.425M113.425M83.153M49.869M41.167M
cost of revenue2.155M2.155M909.00K626.00K176.00K
gross profit111.27M111.27M82.244M49.243M40.991M
gross profit ratio0.9810.9810.9890.9870.996
research and development expenses47.57M47.57M50.077M51.62M58.485M
general and administrative expenses0036.356M023.793M
selling and marketing expenses000018.272M
selling general and administrative expenses37.744M37.744M36.356M40.016M42.065M
other expenses-164.00K-164.00K-8.00K2.232M2.74M
operating expenses85.314M85.314M86.433M91.636M100.55M
cost and expenses87.469M87.469M87.342M92.262M100.726M
interest income4.844M4.844M1.905M2.169M0
interest expense1.054M1.054M1.079M853.00K971.00K
depreciation and amortization4.68M4.68M427.00K2.232M2.74M
ebitda30.636M30.636M-2.292M-40.161M-56.819M
ebitda ratio0.270.27-0.028-0.805-1.38
operating income25.956M25.956M-4.189M-42.393M-59.559M
operating income ratio0.2290.229-0.05-0.85-1.447
total other income expenses net-164.00K-164.00K-8.00K1.379M1.769M
income before tax29.582M29.582M-3.371M-41.014M-57.79M
income before tax ratio0.2610.261-0.041-0.822-1.404
income tax expense-1.166M-1.166M877.00K-448.00K1.218M
net income30.748M30.748M-4.248M-40.566M-59.008M
net income ratio0.2710.271-0.051-0.813-1.433
eps0.100.10-0.016-0.16-0.23
eps diluted0.100.10-0.016-0.16-0.23
weighted average shs out273.341M273.341M263.446M258.848M254.405M
weighted average shs out dil287.59M287.59M263.446M258.848M254.405M
Graph

IMGN Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2023-09-302023-06-302023-03-312022-12-312022-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20232023202320222022
periodQ3Q2Q1Q4Q3
cash and cash equivalents605.535M571.987M201.249M275.138M309.511M
short term investments00000
cash and short term investments605.535M571.987M201.249M275.138M309.511M
net receivables130.694M79.964M31.046M17.978M4.191M
inventory5.495M3.233M614.00K16.196M0
other current assets22.15M14.089M10.955M11.005M16.714M
total current assets736.229M571.987M201.249M275.138M330.416M
property plant equipment net17.227M12.773M13.694M14.608M15.283M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets68.645M129.567M73.402M59.19M13.10M
total non current assets85.872M142.34M87.096M73.798M28.383M
other assets00000
total assets822.101M714.327M288.345M348.936M358.799M
account payables24.853M18.441M32.26M45.353M20.178M
short term debt-24.853M4.334M4.213M4.096M3.981M
tax payables00000
deferred revenue37.186M14.389M13.444M13.856M15.079M
other current liabilities97.474M56.538M51.712M58.553M64.404M
total current liabilities134.66M93.702M101.629M121.858M103.642M
long term debt72.113M71.957M10.049M11.148M12.217M
deferred revenue non current26.718M30.217M34.055M36.355M38.732M
deferred tax liabilities non current00000
other non current liabilities27.014M27.609M20.694M23.749M26.201M
total non current liabilities125.845M129.783M64.798M71.252M77.15M
other liabilities00000
capital lease obligations7.759M13.254M14.262M15.244M16.198M
total liabilities260.505M223.485M166.427M193.11M180.792M
preferred stock00000
common stock2.435M2.374M2.261M2.26M2.208M
retained earnings-1.709B-1.739B-1.735B-1.694B-1.635B
accumulated other comprehensive income loss2.27B2.23B1.857B00
other total stockholders equity-2.435M-2.374M-2.261M1.848B1.811B
total stockholders equity561.596M490.842M121.918M155.826M178.007M
total equity561.596M490.842M121.918M155.826M178.007M
total liabilities and stockholders equity822.101M714.327M288.345M348.936M358.799M
minority interest00000
total investments00000
total debt72.113M71.957M14.262M15.244M16.198M
net debt-533.422M-500.03M-186.987M-259.894M-293.313M
Graph

IMGN Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2023-09-302023-06-302023-03-312022-12-312022-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20232023202320222022
periodQ3Q2Q1Q4Q3
deferred income tax61.397M0000
stock based compensation7.80M7.433M7.067M10.753M5.482M
change in working capital-69.197M-68.553M-38.916M-9.534M10.209M
accounts receivables-56.643M-48.018M-14.746M-12.554M867.00K
inventory-12.554M-4.309M-709.00K-16.196M0
accounts payables6.504M-13.924M-12.975M25.046M2.938M
other working capital-6.504M-2.302M-10.486M-5.83M6.404M
other non cash items-28.401M-1.80M-1.304M-2.838M-2.57M
net cash provided by operating activities2.77M-66.741M-73.719M-60.199M-64.21M
investments in property plant and equipment-1.354M-78.00K-209.00K-248.00K-602.00K
acquisitions net00000
purchases of investments00000
sales maturities of investments00000
other investing activites00000
net cash used for investing activites-1.354M-78.00K-209.00K-248.00K-602.00K
debt repayment0-71.818M000
common stock issued-34.00K365.739M39.00K25.649M0
common stock repurchased00000
dividends paid00000
other financing activites32.166M143.636M0425.00K449.00K
net cash used provided by financing activities32.132M437.557M39.00K26.074M449.00K
effect of forex changes on cash1.000000
net change in cash33.548M370.738M-73.889M-34.373M-64.363M
cash at end of period605.535M571.987M201.249M275.138M309.511M
cash at beginning of period571.987M201.249M275.138M309.511M373.874M
operating cashflow2.77M-66.741M-73.719M-60.199M-64.21M
capital expenditure-1.354M-78.00K-209.00K-248.00K-602.00K
free cash flow1.416M-66.819M-73.928M-60.447M-64.812M
Graph

Frequently Asked Questions

How did ImmunoGen, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, IMGN generated $113.43M in revenue last quarter, while its costs came in at $2.16M.

Last quarter, how much Gross Profit did ImmunoGen, Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. ImmunoGen, Inc. reported a $111.27M Gross Profit for the quarter ended Sep 30, 2023.

Have IMGN's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. IMGN incurred $85.31M worth of Operating Expenses, while it generated $25.96M worth of Operating Income.

How much Net Income has IMGN posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from ImmunoGen, Inc., the company generated $30.75M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did ImmunoGen, Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to ImmunoGen, Inc. as of the end of the last quarter was $605.54M.

What are IMGN's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, IMGN had Total Net Receivables of $130.69M.

In terms of Total Assets and Current Assets, where did ImmunoGen, Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of IMGN were $736.23M, while the Total Assets stand at $822.10M.

As of the last quarter, how much Total Debt did ImmunoGen, Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of IMGN's debt was $72.11M at the end of the last quarter.

What were IMGN's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, IMGN reported total liabilities of $260.51M.

How much did IMGN's Working Capital change over the last quarter?

Working Capital Change for IMGN was -$69.20M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

IMGN generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. IMGN generated $2.77M of Cash from Operating Activities during its recently reported quarter.

What was IMGN's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. IMGN reported a $33.55M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph